Published in World J Gastroenterol on October 07, 2008
Bile acids: regulation of synthesis. J Lipid Res (2009) 4.31
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil (2010) 1.60
Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res (2009) 1.36
TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep (2012) 1.23
Allelic variation of bile salt hydrolase genes in Lactobacillus salivarius does not determine bile resistance levels. J Bacteriol (2009) 1.01
Excretion of biliary compounds during intrauterine life. World J Gastroenterol (2009) 0.85
Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations. Mol Aspects Med (2013) 0.85
Waking action of ursodeoxycholic acid (UDCA) involves histamine and GABAA receptor block. PLoS One (2012) 0.80
Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos (2012) 0.79
Bile acids induce hepatic differentiation of mesenchymal stem cells. Sci Rep (2015) 0.78
Bile acids: emerging role in management of liver diseases. Hepatol Int (2015) 0.78
A shift in paradigm towards human biology-based systems for cholestatic-liver diseases. J Physiol (2015) 0.76
Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World J Gastroenterol (2016) 0.76
The role of bile salts in liver regeneration. Hepatol Int (2016) 0.75
Bile Acids Act as Soluble Host Restriction Factors Limiting Cytomegalovirus Replication in Hepatocytes. J Virol (2016) 0.75
Comparison of Cytotoxic Activity of Bile on HepG2 and CCRF-CEM Cell Lines: An in Vitro Study. Iran J Med Sci (2012) 0.75
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest (2002) 21.08
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature (2006) 9.36
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev (2000) 9.09
Identification of a nuclear receptor for bile acids. Science (1999) 7.81
PPARs and the complex journey to obesity. Nat Med (2004) 7.44
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell (2000) 7.18
Bile acids: natural ligands for an orphan nuclear receptor. Science (1999) 7.18
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell (2000) 6.71
Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell (2000) 6.48
The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem (2003) 6.35
Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science (2006) 5.52
A G protein-coupled receptor responsive to bile acids. J Biol Chem (2003) 4.76
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Identification of a nuclear receptor that is activated by farnesol metabolites. Cell (1995) 3.92
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev (2003) 3.74
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest (2006) 3.44
Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun (2002) 3.41
Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun (2005) 3.38
Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res (2007) 3.37
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 3.33
LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol (2006) 3.11
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A (2006) 3.05
Endocrine functions of bile acids. EMBO J (2006) 3.03
Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med (1978) 2.92
Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res (2003) 2.88
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem (2001) 2.70
Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell (2002) 2.68
Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem (2001) 2.58
Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest (2003) 2.51
Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology (2004) 2.44
Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev (2002) 2.41
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem (2001) 2.37
Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem (2003) 2.26
A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun (1970) 2.24
The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology (2001) 2.20
Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology (2004) 2.20
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem (2002) 1.97
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest (1986) 1.96
Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology (2008) 1.95
Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem (2004) 1.90
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem (2008) 1.85
The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol (2005) 1.84
Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun (2008) 1.83
Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology (2006) 1.80
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology (2005) 1.79
Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest (1997) 1.75
Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J (2006) 1.70
The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology (2007) 1.69
Swelling of rat hepatocytes stimulates glycogen synthesis. J Biol Chem (1990) 1.68
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67
Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol (2001) 1.66
Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol (2006) 1.64
Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes (2004) 1.63
Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem (2003) 1.61
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology (2007) 1.59
The role of cellular hydration in the regulation of cell function. Biochem J (1996) 1.58
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem (2001) 1.54
Cell volume in the regulation of hepatic function: a mechanism for metabolic control. Biochim Biophys Acta (1991) 1.51
Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem (1999) 1.50
Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem (2003) 1.44
Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology (2004) 1.36
The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J Surg Res (1994) 1.36
Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology (2002) 1.31
The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol (2000) 1.31
Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. Gastroenterology (1999) 1.26
Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology (2005) 1.24
Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med (1994) 1.21
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology (2002) 1.20
Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J Biol Chem (2001) 1.20
Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism (1982) 1.19
Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem (2003) 1.18
Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol (2007) 1.17
Bile acid interactions with cholangiocytes. World J Gastroenterol (2006) 1.16
Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med (1987) 1.16
Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology (2003) 1.15
Cell volume regulation in liver. Ren Physiol Biochem (1989) 1.15
Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol (2003) 1.15
Identification of a bile acid response element in the cholesterol 7 alpha-hydroxylase gene CYP7A. Am J Physiol (1997) 1.14
Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem (2004) 1.14
Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol (2004) 1.12
Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J Biol Chem (2000) 1.11
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology (2003) 1.11
Cell volume is a major determinant of proteolysis control in liver. FEBS Lett (1991) 1.10
Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem (2003) 1.09
Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem (2003) 1.07
Cell hydration controls autophagosome formation in rat liver in a microtubule-dependent way downstream from p38MAPK activation. Biochem J (2001) 1.07
Prevention of postoperative renal failure in patients with obstructive jaundice--the role of bile salts. Br J Surg (1983) 1.06
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology (1992) 1.06
Cell volume and bile acid excretion. Biochem J (1992) 1.05
Involvement of integrins in osmosensing and signaling toward autophagic proteolysis in rat liver. J Biol Chem (2003) 1.05
Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol (2006) 1.03
Bile acids stimulate proliferative and secretory events in large but not small cholangiocytes. Am J Physiol (1997) 1.03
Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology (1996) 1.03
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology (2008) 4.53
Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med (2005) 3.24
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun (2006) 2.54
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
Rickettsia felis infection acquired in Europe and documented by polymerase chain reaction. Emerg Infect Dis (2002) 2.26
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology (2002) 2.16
Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med (2007) 2.14
iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science (2012) 2.14
An obligatory requirement for the heterotrimeric G protein Gi3 in the antiautophagic action of insulin in the liver. Proc Natl Acad Sci U S A (2007) 2.10
IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J (2003) 2.00
Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A (2011) 1.98
Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology (2014) 1.93
Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun (2008) 1.83
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology (2005) 1.79
Hepatic stellate cells contribute to progenitor cells and liver regeneration. J Clin Invest (2014) 1.77
Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol (2011) 1.71
The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology (2007) 1.69
Early clinical experiences with the new influenza A (H1N1/09). Dtsch Arztebl Int (2009) 1.65
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol (2004) 1.64
The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology (2009) 1.62
Lipopolysaccharide-induced tyrosine nitration and inactivation of hepatic glutamine synthetase in the rat. Hepatology (2005) 1.62
Ultrasound in tropical and parasitic diseases. Lancet (2003) 1.59
Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol (2004) 1.55
Benzodiazepine-induced protein tyrosine nitration in rat astrocytes. Hepatology (2003) 1.53
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr (2006) 1.53
Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem (2005) 1.53
Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells (2005) 1.53
α5 β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology (2012) 1.50
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res (2010) 1.43
Effective T-cell recall responses require the taurine transporter Taut. Eur J Immunol (2012) 1.42
The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal (2012) 1.40
The niche of stellate cells within rat liver. Hepatology (2009) 1.40
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol (2009) 1.38
Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. Hepatology (2010) 1.33
Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med (2004) 1.31
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther (2010) 1.31
Hepatic stem cell niches. J Clin Invest (2013) 1.29
Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. J Immunol (2007) 1.27
Hepatic encephalopathy and fitness to drive. Gastroenterology (2009) 1.26
Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology (2005) 1.24
Co-reactivity of plasmodial histidine-rich protein 2 and aldolase on a combined immuno-chromographic-malaria dipstick (ICT) as a potential semi-quantitative marker of high Plasmodium falciparum parasitaemia. Parasitol Res (2004) 1.24
Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology (2002) 1.23
Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J (2001) 1.21
Involvement of Toso in activation of monocytes, macrophages, and granulocytes. Proc Natl Acad Sci U S A (2013) 1.19
Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia (2007) 1.16
Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int (2006) 1.16
Phenotype of the taurine transporter knockout mouse. Methods Enzymol (2007) 1.16
Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation. FASEB J (2003) 1.14
Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase. Gastroenterology (2004) 1.13
Reversible inhibition of mammalian glutamine synthetase by tyrosine nitration. FEBS Lett (2006) 1.12
The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia (2010) 1.12
Late-phase pulse-inversion sonography using the contrast agent levovist: differentiation between benign and malignant focal lesions of the liver. AJR Am J Roentgenol (2002) 1.11
Neural mechanism underlying impaired visual judgement in the dysmetabolic brain: an fMRI study. Neuroimage (2004) 1.10
Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun (2007) 1.09
Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised. FASEB J (2004) 1.08
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes. FASEB J (2002) 1.07
Correct determination of critical flicker frequency is mandatory when comparisons to other tests are made. Gut (2013) 1.06
Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother (2007) 1.06
Evaluation of acoustic radiation force impulse imaging for determination of liver stiffness using transient elastography as a reference. World J Gastroenterol (2012) 1.05
Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology (2002) 1.05
The virtual liver: state of the art and future perspectives. Arch Toxicol (2014) 1.05
Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Gastroenterology (2003) 1.05
Involvement of integrins in osmosensing and signaling toward autophagic proteolysis in rat liver. J Biol Chem (2003) 1.05
The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol (2012) 1.04
Involvement of integrins and Src in insulin signaling toward autophagic proteolysis in rat liver. J Biol Chem (2004) 1.04
Enhanced insulin sensitivity of gene-targeted mice lacking functional KCNQ1. Am J Physiol Regul Integr Comp Physiol (2009) 1.04
Prevention of bile acid-induced apoptosis by betaine in rat liver. Hepatology (2002) 1.02
Plasmodium malariae infection in spite of previous anti-malarial medication. Parasitol Res (2007) 1.01
Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology (2006) 1.01
The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem (2010) 1.01
Chronic liver disease is triggered by taurine transporter knockout in the mouse. FASEB J (2006) 1.01
The osmolyte strategy of normal human keratinocytes in maintaining cell homeostasis. J Invest Dermatol (2004) 1.00
Usp18 driven enforced viral replication in dendritic cells contributes to break of immunological tolerance in autoimmune diabetes. PLoS Pathog (2013) 0.99
Ca2+-dependent protein kinase C isoforms induce cholestasis in rat liver. J Biol Chem (2003) 0.99
Hepatic and pancreatic stellate cells in focus. Biol Chem (2009) 0.99
Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology (2006) 0.99
Microglia activation in hepatic encephalopathy in rats and humans. Hepatology (2011) 0.99
Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol (2012) 0.98
Hyperosmotic activation of the CD95 system. Methods Enzymol (2007) 0.98
Assessment of low-grade hepatic encephalopathy: a critical analysis. J Hepatol (2007) 0.98
Differential and synergistic effects of platelet-derived growth factor-BB and transforming growth factor-beta1 on activated pancreatic stellate cells. Pancreas (2005) 0.97